Cargando…

A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes

OBJECTIVE: We aimed to identify a novel panel of biomarkers predicting renal function decline in type 2 diabetes, using biomarkers representing different disease pathways speculated to contribute to the progression of diabetic nephropathy. RESEARCH DESIGN AND METHODS: A systematic data integration a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pena, Michelle J., Heinzel, Andreas, Heinze, Georg, Alkhalaf, Alaa, Bakker, Stephan J. L., Nguyen, Tri Q., Goldschmeding, Roel, Bilo, Henk J. G., Perco, Paul, Mayer, Bernd, de Zeeuw, Dick, Lambers Heerspink, Hiddo J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431870/ https://www.ncbi.nlm.nih.gov/pubmed/25973922 http://dx.doi.org/10.1371/journal.pone.0120995

Ejemplares similares

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2019)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

How to measure and monitor albuminuria in healthy toddlers?
por: van den Belt, Sophie Marielle, et al.
Publicado: (2018)

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
por: Sinkeler, Steef J., et al.
Publicado: (2013)

Improving clinical trial efficiency by biomarker-guided patient selection
por: Boessen, Ruud, et al.
Publicado: (2014)

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
por: Hellemons, Merel E., et al.
Publicado: (2012)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease
por: Gregorich, Mariella, et al.
Publicado: (2023)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies
por: Olde Engberink, Rik H. G., et al.
Publicado: (2016)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2019)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
por: Heerspink, Hiddo J Lambers, et al.
Publicado: (2009)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]
por: Roscioni, S. S., et al.
Publicado: (2011)

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study
por: Meems, Laura M. G., et al.
Publicado: (2016)

Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Mijnhout, Gerritje S., et al.
Publicado: (2012)

Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus
por: Pena, Michelle J., et al.
Publicado: (2016)

Longitudinal relationship between albuminuria in infancy and childhood
por: Gracchi, Valentina, et al.
Publicado: (2023)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
por: Heerspink, H J Lambers, et al.
Publicado: (2013)

Plasma COOH-Terminal Proendothelin-1: A marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29)
por: Drion, Iefke, et al.
Publicado: (2012)

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
por: Bakker, Elisabeth, et al.
Publicado: (2021)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action
por: Heinzel, Andreas, et al.
Publicado: (2014)

N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk
por: Idzerda, Nienke M. A., et al.
Publicado: (2018)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer
por: Andorfer, Peter, et al.
Publicado: (2016)

Machine‐learning–based early prediction of end‐stage renal disease in patients with diabetic kidney disease using clinical trials data
por: Belur Nagaraj, Sunil, et al.
Publicado: (2020)

Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998–2004: a longitudinal observational study
por: Greving, Jacoba P, et al.
Publicado: (2007)

Effect of Benfotiamine on Advanced Glycation Endproducts and Markers of Endothelial Dysfunction and Inflammation in Diabetic Nephropathy
por: Alkhalaf, Alaa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_chocmpapackuqbo6f6fv989e4g